Filing Flows › AstraZeneca (AZN) › Gross margin
AstraZeneca (AZN) gross margin by quarter
AstraZeneca's gross margin was 81.8% in Q3 2026 (third quarter 2026), -1.8 pts from Q2 2026. Over the last 5 quarters it ranged from 81.6% (Q3 2025) to 83.6% (Q2 2026).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 81.8% | -1.8 pts | +0.3 pts |
| Q2 2026 | 83.6% | +1.1 pts | +0.7 pts |
| Q1 2026 | 82.5% | +0.9 pts | — |
| Q3 2025 | 81.6% | -1.3 pts | — |
| Q2 2025 | 82.9% | — | — |
Q3 2026 at a glance
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart follows the revenue to costs, profit and cash.
Questions
What is AstraZeneca's gross margin?
AstraZeneca's gross margin was 81.8% in Q3 2026 (third quarter 2026), -1.8 pts from Q2 2026.
How has AstraZeneca's gross margin changed?
Over the last 5 quarters it ranged from 81.6% (Q3 2025) to 83.6% (Q2 2026).